1 / 49

Prevention of ovarian hyperstimulation syndrome in OHSS patients

Prevention of ovarian hyperstimulation syndrome in OHSS patients. Georg Griesinger University Clinic of Schleswig-Holstein, Campus Luebeck Dept. of Obstetrics and Gynecology. VVOG Post-Universitaire Studiedag Zemst, 13 Nov 2008. What is the OHSS incidence in your center?.

rriffe
Download Presentation

Prevention of ovarian hyperstimulation syndrome in OHSS patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Prevention of ovarian hyperstimulation syndrome in OHSS patients Georg Griesinger University Clinic of Schleswig-Holstein, Campus Luebeck Dept. of Obstetrics and Gynecology VVOG Post-Universitaire Studiedag Zemst, 13 Nov 2008

  2. What is the OHSS incidence in your center?

  3. German IVF registry, 2006

  4. Number of OHSS cases per year in Germany? • 0,41 (incidence DIR) x ~40.000 IVF cycles with ovarian stimulation per year = 164 OHSS cases

  5. = 1.080 OHSS III cases per year in Germany Hum Reprod. 2006 Dec;21(12):3235-40

  6. OHSS III° incidence: 2,1% 95% CI: 1.6 – 2.8 Fertility and Sterility Vol. 85, No. 1, 2006

  7. OHSS [MeSH] AND fatality [MeSH] • death of a 31-year-old woman …who developed a fatal adult respiratory distress syndromeFineschi et al., 2006 • autopsy case of severe OHSS …..28-year-old Japanese female…… who died of rapid respiratory insufficiencySemba et al., 2000 • 21 yearoldwoman ……cerebralinfarction….complete persistent hemiplegia Hwang et al., 1998 • ........................

  8. primaryprevention: intendedtodecreasetheoverallrisk in thegeneralpopulation • secondaryprevention: detectionofpatients atriskandpreventivemeasureonly in thosepatients • tertiaryprevention: prophylaxisoffurtherdamage in patientswith a disease

  9. Can we reliably predict OHSS?

  10. Long GnRH-agonist protocol De Angelo et al., 2004 E2 = 3,354 pg/ml Sens + Spec = 85% GnRH-antagonist protocol Papanicolaou et al., 2006 18 follicles >10 mm or E2 > 5,000 pg/l Sens = 83% Spec = 84% 5/53 CASES OF SEVERE OHSS STILL MISSED WITH THESE CRITERIA

  11. Noreliabletesttoidentify all OHSS riskpatients • developovarianstimulationroutinesthatareassociatedwith a per se decreasedriskof OHSS (primaryprevention) • developmeasuresof OHSS preventionfor individual riskpatients, whicharesafeandefficacious, andcanthereforebeliberallyutilized (secondaryprevention) • developbettertreatmentregimenforpatientswithonsetof OHSS toavoidfurthercomplications (tertiaryprevention)

  12. OHSS Prevention

  13. Ovarian stimulation • OHSS incidence reduction • Natural cycle IVF √ • In vitro Maturation √ • Cycle cancellation √ efficacy ? ? ---

  14. Number-needed-to-treat-to-harm with a GnRH-agonist long protocol for OHSS III Kolibianakis et al., Hum Reprod Update 2006 EXPECTED OHSS III° INCIDENCE: 3.5% RR = 0.47, 95% CI 0.27–0.82, P = 0.01 NNT TO HARM = 53 (39 - 159) 3,46%

  15. GnRH-antagonist vs GnRH-agonist long OHSS III Crude incidence of OHSS = 1.5%

  16. A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial Incidence of OHSS = 1.4% Heijnen et al.,Lancet 2007; 369: 743–49

  17. Coasting OHSS II-III in 3-10% Delvigne & Rozenberg, HRupdate, 2002

  18. GnRH -antagonists

  19. Novel concepts in Coasting E2 < 3000 pg/ml ? 4 follicles ≥ 16mm? Hyper response? hCG FSH FSH GnRH-agonist daily GnRH-antagonist daily n= 85, coasting ~ 1.5 days Ongoing pregnancy rate: ~ 60 % Severe OHSS: 1.5 - 7.5 % Gustofson et al., Hum Reprod 2006 Gustofson et al., Fertil Steril 2006

  20. Novel concepts in Coasting RCT: 192 patients Aboulghar et al., RBMonline 2007

  21. Coasting in Antagonist protocols Bahceci et al., 2006; Farhi et al., 2008

  22. Ovarian stimulation

  23. OHSS Prevention

  24. The final solutionto OHSS prevention….. • AbolishhCGas a triggeringagent!?

  25. GnRH-agonisttrigger Gonen et al., 1990

  26. Luteal phase after agonist trigger? • Progesteroneserumvalueswith • NO • lutealphasesupplementation Day ofadministrationofGnRH-a orhCG Beckers et al., 2003

  27. Drastic luteolysis… • Will itprevent OHSS? Kol S, Fertil Steril 2004

  28. Does GnRH-agonist triggering prevent OHSS? RCT

  29. OHSS I-II: RR with 95% confidence intervals (heterogeneity p = 0.57) OHSS III: RR with 95% confidenceintervals (heterogeneity p = 0.90) Update of: Griesinger et al., Hum Reprod update 2005

  30. Evidence from observational, uncontrolled trials16 publicationstotal n= 1,091 OHSS risk patients  a single case reported: late-onset OHSS in a pregnant woman Update of: Griesinger et al., RBMonline 2006

  31. No difference between • 0.2 triptorelin or 0.5 mg buserelin and hCG • no. of oocytes • no. of MII oocytes • fertilisationrate • embryo Score • BUT: • ongoing PR drastically reduced Human Reproduction Update, 2006

  32. Griesinger et al., Hum Reprod 2007

  33. Cryopreservation slow cooling vitrification 2 sec. - 50.000°C/min

  34. Update of Griesinger et al., Hum Reprod 2007

  35. Update of Griesinger et al., Hum Reprod 2007

  36. Mean number of ETs: 2.1 Mean number of embryos transferred 2.1 Mean time-to-conception 21 weeks Cumulative incidence positive hCG test leading to live birth

  37. Reduced hCG dose? • RCT, n= 80 PCOS • GnRH-antagonist protocol Kolibianakis et al., 2007

  38. low dose hCG & OHSS? • Retrospective study, n=94 cycles • > 2,500 - 4,000 pg/mL  5000 IU • >4000  3300 IU Schmidt et al., 2007

  39. Half dose/low dose hCG & OHSS? • Observational pilot study • 2.500 vs. 5.000 IU hCG • n = 21 OHSS high-risk patients • 62% ongoing pregnancy rate • 0 % OHSS Nargund et al., 2007 Craft, 2007

  40. OHSS Prevention

  41. Clinical pregnancy rate per ET Griesinger, GebFra 2006

  42. Novel concept: Luteal phase antagonist hCG 3 dayslater…. early OHSS GnRH-antagonist daily GnRH-antagonist daily FSH Report on 3 cases with early-onset OHSS Lainas et al., RBMonline 2007

  43. Novel concepts: cabergoline VEGF

  44. Novel concepts in treatment: Cabergolin Background: Vascular fluid leakage VEGF VEGF R1 Cabergoline Dopamine R agonist Alvarez et al, JCEM 2007

  45. RCT: placebo-controlled Intervention: Cab 0.5 mg, day hCG  hCG+8 Patients: oocyte donors Inclusion: > 20 oocytes retrieved Alvarez et al, JCEM 2007 & Alvarez, Hum Reprod 2007

More Related